COMPARISON
Oxytocin vs Vasopressin
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Oxytocin is authorised or registered in 9 and Vasopressin in 7 of the 10 registers read. Oxytocin: highest phase Phase 4 (after approval). Vasopressin: highest phase Phase 4 (after approval). 31 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Oxytocin | Vasopressin | |
|---|---|---|
| Registered trials differs | 952 clinicaltrials.gov · 2026-10-03 | 449 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA label, application not recorded: GUNA-GERIATRICS openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VASOPRESSIN openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
LEGAL STATUS
Approval in each country read
| Country | Oxytocin | Vasopressin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
31 registered trials include both
| NCT07838493 | Oromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention RECRUITING · updated 2026-09-24 |
|---|---|
| NCT07568509 | Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease RECRUITING · updated 2026-08-21 |
| NCT04789148 | Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency RECRUITING · updated 2026-07-23 |
| NCT06460948 | Identifying Oxytocin Deficiency in Adults With Pituitary Disease COMPLETED · updated 2026-05-13 |
| NCT06036004 | Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus RECRUITING · updated 2026-05-06 |
| NCT07276152 | Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology RECRUITING · updated 2026-02-13 |
| NCT07143266 | Sleep Disorders in Hypothalamic and Pituitary Damage RECRUITING · updated 2025-11-18 |
| NCT05766852 | Potential Benefits of the Somatic Psychoeducational Intervention COMPLETED · updated 2025-11-10 |
| NCT06605300 | The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling COMPLETED · updated 2025-10-03 |
| NCT06808516 | Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls RECRUITING · updated 2025-10-03 |
| NCT06676774 | Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and He RECRUITING · updated 2025-05-23 |
| NCT06789705 | Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls RECRUITING · updated 2025-02-19 |
| NCT03602521 | Reactivity of Patients With Borderline Personality Disorder to an Ecological Interpersonal Stress COMPLETED · updated 2023-12-20 |
| NCT04890470 | Effects of Oxytocin and Vasopressin on Moral Decision Making COMPLETED · updated 2023-09-21 |
| NCT05920707 | Common and Differentiated Representations Between Social Exclusion and Social Separation UNKNOWN · updated 2023-06-28 |
| NCT02255357 | Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients. COMPLETED · updated 2023-06-05 |
| NCT05806307 | Methods Decreasing Bleeding in Open Myomectomy UNKNOWN · updated 2023-04-10 |
| NCT03101826 | Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory TERMINATED · updated 2023-04-03 |
| NCT04648137 | Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls COMPLETED · updated 2022-04-13 |
| NCT04715737 | Differential Effects of Vasopressin and Oxytocin on Attention Control COMPLETED · updated 2021-01-22 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.